MDV3100
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Castration-Resistant Prostate Cancer
Conditions
Metastatic Castration-Resistant Prostate Cancer
Trial Timeline
— → —
NCT ID
NCT01606982About MDV3100
MDV3100 is a pre-clinical stage product being developed by Astellas Pharma for Metastatic Castration-Resistant Prostate Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01606982. Target conditions include Metastatic Castration-Resistant Prostate Cancer.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01606982 | Pre-clinical | Completed |
| NCT01911741 | Phase 1 | Completed |
| NCT01565928 | Phase 1 | Completed |
| NCT01901133 | Phase 1 | Completed |
| NCT01911715 | Phase 1 | Completed |
| NCT01284920 | Phase 1/2 | Completed |
| NCT00510718 | Phase 1 | Completed |
Competing Products
20 competing products in Metastatic Castration-Resistant Prostate Cancer